Peripheral IgM+ memory B cells were identified to be associated with the responses to anti-PD-1 monotherapy in advanced NSCLC patients, providing the evidence on peripheral B cell signatures as a potential biomarker for stratifying the patients before the treatment. The gene discussed is CD40LG; the disease is non-small cell lung carcinoma.